High Costs, Low Margins, and Regulatory Hurdles Hinder Pharma’s Adoption of Advanced Manufacturing Technologies

Benchmark Banner Ad

 

The ongoing drug shortage crisis in the U.S. underscores a critical need for innovation in pharmaceutical manufacturing. As manufacturing issues, outdated technologies, and geopolitical risks contribute to shortages that impact patient care and elevate healthcare costs, the introduction of Advanced Manufacturing Technologies (AMTs) offers a beacon of hope. AMT technologies promise to enhance quality control and reduce production downtime, yet their adoption in generic drug production remains low despite obvious benefits.

Why is the pharmaceutical industry slow to adopt technologies that could revolutionize drug availability and cost?

Mike Tracy, a C-Level Healthcare Operations Strategist, dives into the complexities of integrating Advanced Manufacturing Technologies in drug production. Mike points out that while AMTs can drastically reduce bottlenecks in drug production, the significant initial investment and stringent regulatory landscape pose substantial hurdles.

“Every AMT has a high startup cost and generic drugs have very razor-thin margins to begin with. We’re not talking about a new drug that’s not already out in the market where you’re going to have a high margin and it makes sense to invest millions,” Tracy explains.

Article written by Sonia Gossai

Follow us on social media for the latest updates in B2B!

Image

Latest

business insights
Amberd Delivers Real-Time Business Insights, Cutting Executive Reporting From Weeks to Minutes With ADA
February 18, 2026

Many organizations struggle to deliver real-time business insights to executives. Traditional workflows require analysts and database teams to extract, prepare, and validate data before it reaches decision makers. That process can stretch across departments and delay critical answers.. Mazda Marvasti, CEO of Amberd, says the cycle to answer a single business question can take…

Read More
AI costs
QumulusAI Brings Fixed Monthly Pricing to Unpredictable AI Costs in Private LLM Deployment
February 18, 2026

Unpredictable AI costs have become a growing concern for organizations running private LLM platforms. Usage-based pricing models can drive significant swings in monthly expenses as adoption increases. Budgeting becomes difficult when infrastructure spending rises with every new user interaction. Mazda Marvasti, CEO of Amberd, says pricing volatility created challenges as his team expanded its…

Read More
GPU infrastructure
Amberd Moves to the Front of the Line With QumulusAI’s GPU Infrastructure
February 18, 2026

Reliable GPU infrastructure determines how quickly AI companies can execute. Teams developing private LLM platforms depend on consistent high-performance compute. Shared cloud environments often create delays when demand exceeds available capacity Mazda Marvasti, CEO of Amberd, says waiting for GPU capacity did not align with his company’s pace. Amberd required guaranteed availability to support…

Read More
private LLM
QumulusAI Secures Priority GPU Infrastructure Amid AWS Capacity Constraints on Private LLM Development
February 18, 2026

Developing a private large language model(LLM) on AWS can expose infrastructure constraints, particularly around GPU access. For smaller companies, securing consistent access to high-performance computing often proves difficult when competing with larger cloud customers. Mazda Marvasti, CEO of Amberd AI,  encountered these challenges while scaling his company’s AI platform. Because Amberd operates its own…

Read More